VTA yields 122.59% · PFE yields 6.13%● Live data
📍 VTA pulled ahead of the other in Year 1
Combined, VTA + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VTA + PFE for your $10,000?
Invesco Dynamic Credit Opportunities Fund is a diversified closed-end management investment company. The Fund's investment objective is to seek a high level of current income, with a secondary objective of capital appreciation. The Fund invests primarily in a portfolio of interests in floating or variable senior loans to corporations, partnerships and other entities, which operate in a range of industries and geographic regions. The Fund invests in various sectors, which include business equipment and services; electronics and electrical; retailers (except food and drug); telecommunications; utilities; food products; healthcare; leisure goods, activities and movies; lodging and casinos; oil and gas; containers and glass products; structured products; cable and satellite television, and financial intermediaries. It may invest in senior loans to borrowers that are organized or located in countries other than the United States. The Fund's investment advisor is Invesco Advisers, Inc.
Full VTA Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.